Bayer shares down 7% after U.S. court says it will review Monsanto case

Bayer shares down 7% after U.S. court says it will review Monsanto case


Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany.

Wolfgang Rattay | Reuters

Shares of German life sciences company Bayer fell nearly 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure to products of the company’s Monsanto unit harmed individuals.

The Washington Supreme Court this week accepted a review of litigation against the German company over the impact of polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center in Washington state, one of many related cases Bayer is fighting. Previously, an appeals court had overturned a $185 million award in the trial after finding flaws in the case in May, according to Reuters.

Bayer shares were 6.76% lower at 12:45 p.m. London time, putting the stock on course for its worst performance since March and extending a loss of 13% in the year to date. Shares had tumbled more than 30% last year amid challenges including ongoing litigation over the Monsanto unit and high net debt.

The company said in a statement Wednesday that there was “no basis for a different outcome on appeal,” and that it believed the Washington Court of Appeals’ decision had identified three errors in the case, including that testimony for the plaintiffs regarding PCB exposure lacked scientific validity.

Bayer argues the claims relate to industrial materials which Monsanto voluntarily ended manufacture of in 1977.

Bayer acquired U.S. agrichemical-maker Monsanto in 2018.

The deal has led to the company fighting myriad legal challenges in various U.S. courts over alleged negative health effects, including cancer, from exposure to Monsanto products including Roundup weed killer.

According to Reuters, around 125,000 charges have been brought against the product in the U.S., more than half of which had been resolved following a $10.9 billion settlement in 2020.

In September, the company secured a legal win when the 3rd U.S. Circuit Court of Appeals in Philadelphia found in its favor in a claim that Monsanto violated state law by failing to add a cancer warning to the Roundup label.

Stock Chart IconStock chart icon

hide content

Bayer share price.



Source

Tech AI spending may approach 0 billion this year, but the blow to cash raises red flags
World

Tech AI spending may approach $700 billion this year, but the blow to cash raises red flags

A general view of the Google Midlothian Data Center where Texas Gov. Greg Abbott and Alphabet and Google CEO Sundar Pichai are scheduled to speak on Nov. 14, 2025 in Midlothian, Texas. Ron Jenkins | Getty Images Alphabet, Microsoft, Meta and Amazon are expected to spend nearly $700 billion combined this year to fuel their […]

Read More
Time for traders to fade this group of stocks that’s been on a tear, says Carter Worth
World

Time for traders to fade this group of stocks that’s been on a tear, says Carter Worth

(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) The low-beta, long-time laggard S & P 500 Consumer Stapes Sector has come to in a big way the past 3 months, now up 15% in the period versus a 1% gain for the S & P 500 Index itself. Here and now, by […]

Read More
Trump holds leverage over Iran thanks to low oil prices, Energy Secretary says
World

Trump holds leverage over Iran thanks to low oil prices, Energy Secretary says

Low oil prices give President Donald Trump more leverage over Iran, U.S. Energy Secretary Chris Wright said Friday, speaking as the two adversaries teeter on the brink of another conflict. “The world is very well supplied with oil right now, and I think it gives President Trump more leverage in his geopolitical actions to not […]

Read More